Abstracts

882 – Heterogeneity in Community Priorities for HIV Molecular Epidemiology in the US: A Best-Worst Scaling

Background HIV molecular epidemiology (HIV-ME) can support HIV cluster identification, tailor public health interventions, and conduct important research about HIV. Yet HIV-ME has vocal critics and concerns about the ethical, legal, and social implications (ELSI) of HIV-ME remain. We explored heterogeneity in community priorities for HIV-ME and assessed the reliability and validity of the results.…

349 – IL-10 and IFN Signaling Define Epigenetic States Linked to HIV Persistence in Memory CD4+ T Cells

Background HIV persistence during antiretroviral therapy (ART) is sustained by immunoregulatory pathways that suppress antiviral responses. IL-10 has been linked to reservoir size and shown to inhibit interferon stimulated genes (ISG). In SIV-infected rhesus macaques (RMs), anti-IL-10 alone (aIL10) led to partial control of viremia after treatment interruption, highlighting IL-10 as a regulator of reservoir…

1097 – Lost Patients and Missed Cases: Failures of Point-of-Care Diagnostics in Advanced HIV Care

Background Point-of-care (POC) diagnostics are central to the World Health Organisation (WHO) advanced HIV disease (AHD) care package, but their effectiveness in real-world programs is limited by implementation gaps that reduce test performance. We evaluated challenges in POC cryptococcal antigen (CrAg) and CD4 testing across three Médecins Sans Frontières (MSF) supported programs. Methods Evaluations were…

374 – Inducible HIV Reservoirs Display a Senescent-Like Phenotype and Are Sensitive to Senolytics

Background Identifying the mechanisms contributing to the persistence of HIV reservoirs during antiretroviral therapy (ART) is essential to the development of strategies aimed at eradicating them. Since senescent T cells accumulate with age and infection, we hypothesized that the HIV reservoir may preferentially persist in these cells after prolonged ART.  Methods We used a modified…

519 – Efficacy and Safety of Doravirine/Islatravir (100/0.25 mg) in Adults With HIV and Renal Impairment

Background Renal impairment (RI) is a common comorbidity in people living with HIV (PLWH). The availability of safe and effective antiretrovirals (ARVs) in people with RI is important, especially as the population of PLWH ages. DOR/ISL, an investigational once-daily HIV treatment, had a favorable renal safety profile in prior studies with DOR/ISL (100/0.75mg). This post hoc…

822 – Dolutegravir Impedes Cerebral Organoid Maturation

Background The numbers of children born to mothers living with HIV-1 are on the rise. While antiretroviral drugs (ARVs) prevent mother-to-fetus HIV-1 transmission, risks of adverse events on fetal neurodevelopment associated with in utero ARV exposure remain. HIV-1-exposed uninfected (HEU) children exposed in utero to ARVs are known to have poor neurodevelopment across multiple domains including…

564 – Does 4-Class Resistance Affect Low-Level Viremia? A Multicohort Matched Analysis

Background Persistent low-level viremia (LLV; 50-199 copies/mL) is generally considered to confer a modest risk of virological failure (VF; ≥200 copies/mL). Yet, data on LLV in people with HIV (PWH) with multidrug-resistant viruses, particularly those with four-class drug resistance (4DR), remains limited. We therefore aimed to compare the risk of LLV between 4DR- and non-4DR-PWH.…

632 – Plasma Exosomes From Individuals With HIV and Cancer Enhance Tumor Cell Proliferation and Migration

Background People living with HIV (PLWH) achieve near-normal life expectancy with combination antiretroviral therapy (cART); nonetheless, they exhibit a higher incidence of non-AIDS-defining cancers (NADCs) than the non-HIV-infected population. The mechanisms linking HIV infection to NADC development remain poorly understood. Exosomes have emerged as potential mediators of this HIV–cancer axis as both HIV-infected and tumor…